IC-OS Working Group Webinar
Details
Organised by
Date
- America/New_York
Anecita Fadol
Anecita Fadol, PhD, FNP-BC, FAANP, FAAN is an Associate Professor and Education Director, Nursing...
Read MoreAnecita Fadol, PhD, FNP-BC, FAANP, FAAN is an Associate Professor and Education Director, Nursing Cardio-Oncology Program at The University of Texas MD Anderson Cancer Center. Dr. Fadol is a nursing pioneer in the evolving field of cardio-oncology. Her extensive and unique expertise in cardio-oncology have been recognized nationally and internationally. She has written numerous book chapters, published in peer-reviewed journals, and is the editor of the “Cardiac Complications of Cancer Therapy”, the first clinical reference book for nurses that examines the complexity of cardiac problems in conjunction with a cancer diagnosis. Her program of research included the validation of the MD Anderson Symptom Inventory-Heart Failure (MDASI-HF) instrument, which was subsequently translated to Chinese and Spanish. She is on the leadership council for the Cardio-Oncology section of the American College of Cardiology. Dr. Fadol is a fellow of the American Academy of Nurse Practitioners, American Academy of Nursing, and was recently awarded as Honorary Fellow of 2021 by the Hong Kong Academy of Nursing.
Show LessDaniel Lenihan
Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main...
Read MoreDr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
Show LessEdi Pituskin
Edith Pituskin is an associate professor at University of Alberta, Edmonton, Canada.
Read MoreEdith Pituskin is an associate professor at University of Alberta, Edmonton, Canada.
Show LessStephen Casselli
Dr. Stephen Casselli is an executive director at International Cardio-Oncology Society.
Read MoreDr. Stephen Casselli is an executive director at International Cardio-Oncology Society.
Show LessVicki Chambers
Vicki Chambers is a nurse at Royal Brompton Hospital, London, UK.
Read MoreVicki Chambers is a nurse at Royal Brompton Hospital, London, UK.
Show Less